Search ↗

Comparison

FOXO4-DRI vs MOTS-c

Both are mitochondrial & longevity, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, MOTS-c is the better documented of the two (preliminary human). That is a statement about the state of the literature, not a recommendation.

FOXO4-DRI MOTS-c
Class Mitochondrial & longevity Mitochondrial & longevity
Evidence Animal models only Preliminary human
Human trials None published ~3
Half-life ~1-2 hours ~1-2 hours
Reported range 5-25 mg 5-10 mg
Frequency Intermittent research protocols, typically 3 doses per cycle 2-3x weekly
Routes Subcutaneous, Intramuscular Subcutaneous, Intramuscular
FDA approved No No
Research use only Yes Yes
Banned in sport No No
Studied for Senolytic research, Longevity research Metabolic health research, Insulin sensitivity, Exercise capacity research, Longevity
Reported side effects Injection-site reactions, Fatigue, Poorly characterised in humans Injection-site reactions, Transient fatigue, Headache

FOXO4-DRI

FOXO4-DRI is a retro-inverso peptide, built from D-amino acids in reversed sequence, a design that resists proteolysis while preserving the binding surface. It interferes with the interaction between FOXO4 and p53 in senescent cells, releasing p53 to the mitochondria and triggering apoptosis selectively in those cells while sparing healthy ones. The widely circulated result is a mouse study reporting restored fitness, fur density and renal function in aged animals. There is no human data whatsoever.

MOTS-c

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene rather than in nuclear DNA, which makes it unusual among signalling peptides. It regulates the folate-methionine cycle, leading to accumulation of AICAR and consequent AMPK activation, shifting metabolism toward glucose uptake and fatty acid oxidation. Exercise raises endogenous MOTS-c, and levels fall with age, which is the basis of both the exercise-mimetic framing and the longevity interest. Human trial data is limited.

FOXO4-DRI vs MOTS-c: common questions

What is the difference between FOXO4-DRI and MOTS-c?

Both are mitochondrial & longevity. FOXO4-DRI: A senolytic peptide designed to selectively kill senescent cells by disrupting the FOXO4-p53 interaction. MOTS-c: A mitochondria-encoded peptide that acts as an exercise mimetic through AMPK, and one of the better-characterised mitochondrial-derived peptides.

Which has stronger evidence, FOXO4-DRI or MOTS-c?

MOTS-c has the stronger evidence base (preliminary human, about 3 human studies) compared with FOXO4-DRI (animal models only).

Are FOXO4-DRI and MOTS-c FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 167312269) ↗ · structure, identifiers, synonyms
  2. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  3. PubChem compound record (CID 146675088) ↗ · structure, identifiers, synonyms

Published literature

  1. van Willigenburg H, de Keizer PLJ, de Bruin RWF. Cellular senescence as a therapeutic target to improve renal transplantation outcome.Pharmacol Res 2018.PubMed 29471104 · doi:10.1016/j.phrs.2018.02.015
  2. Liu BH, Gu YH, Tu Y, et al.. [Molecular regulative mechanisms of aging and interventional effects of Chinese herbal medicine].Zhongguo Zhong Yao Za Zhi 2017.PubMed 29171222 · doi:10.19540/j.cnki.cjcmm.20170731.001
  3. Alameen AAM, Al-Kuraishy HM, Fawzy MN, et al.. Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline.Naunyn Schmiedebergs Arch Pharmacol 2026.PubMed 42024235 · doi:10.1007/s00210-026-05309-6
  4. Zhang Z, Chen D, Du K, et al.. MOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria.Mitochondrion 2023.PubMed 37307934 · doi:10.1016/j.mito.2023.06.002
  5. Mohtashami Z, Singh MK, Salimiaghdam N, et al.. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases.Int J Mol Sci 2022.PubMed 36233287 · doi:10.3390/ijms231911991
  6. Amado CA, Agüero J, García-Unzueta M, et al.. MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases.J Transl Med 2026.PubMed 42243958 · doi:10.1186/s12967-026-08398-2
  7. Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.Free Radic Biol Med 2016.PubMed 27216708 · doi:10.1016/j.freeradbiomed.2016.05.015
  8. Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.Front Endocrinol (Lausanne) 2023.PubMed 36761202 · doi:10.3389/fendo.2023.1120533
  9. Mendelsohn AR, Larrick JW. Mitochondrial-Derived Peptides Exacerbate Senescence.Rejuvenation Res 2018.PubMed 30058454 · doi:10.1089/rej.2018.2114
  10. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  11. Cuyàs E, Verdura S, Martin-Castillo B, et al.. Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging (Albany NY) 2022.PubMed 36490309 · doi:10.18632/aging.204423

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.